(VIANEWS) – Shares of MDXHEALTH (BEL 20: MDXH.BR) jumped by a staggering 15.73% in 5 sessions from €0.34 to €0.39 at 17:22 EST on Wednesday, after four successive sessions in a row of gains. BEL 20 is sliding 0.12% to €3,652.34, after four sequential sessions in a row of gains.
MDXHEALTH’s last close was €0.38, 56.27% under its 52-week high of €0.87.
About MDXHEALTH
MDxHealth SA, a commercial-stage precision diagnostics company, provides urologic solutions in the United States, Europe, and internationally. Its novel prostate cancer genomic testing solutions are SelectMDx, a non-invasive urine test; and ConfirmMDx, an epigenetic test, which provide physicians with a clinical pathway to identify clinically prostate cancer while minimizing the use of invasive procedures that are prone to complications. The company was formerly known as OncoMethylome Sciences SA and changed its name to MDxHealth SA in October 2010. MDxHealth SA was incorporated in 2003 and is headquartered in Herstal, Belgium.
Earnings Per Share
As for profitability, MDXHEALTH has a trailing twelve months EPS of €-0.28.
Stock Price Classification
According to the stochastic oscillator, a useful indicator of overbought and oversold conditions, MDXHEALTH’s stock is considered to be oversold (<=20).
Earnings Before Interest, Taxes, Depreciation, and Amortization
MDXHEALTH’s EBITDA is 2.67.
Volume
Today’s last reported volume for MDXHEALTH is 978134 which is 91.24% below its average volume of 647262.
More news about MDXHEALTH (MDXH.BR).
